|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein] |
CTD RGD |
PMID:9454827 PMID:15016836 |
RGD:2303194 |
NCBI chr 8:55,401,981...55,415,012
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein] |
CTD RGD |
PMID:9454827 PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions increases response to substance increases activity |
ISO |
Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein] CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein |
CTD |
PMID:10082212 PMID:10216184 |
|
NCBI chr 1:116,715,286...116,837,223
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO EXP |
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein] |
CTD RGD |
PMID:14645658 PMID:15016836 |
RGD:2303194 |
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] |
CTD |
PMID:9454827 |
|
NCBI chr 8:55,418,379...55,436,967
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Tnf |
tumor necrosis factor |
increases activity |
EXP |
TNF results in increased activity of Dimethylphenylpiperazinium Iodide |
CTD |
PMID:15086448 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
affects binding |
EXP |
1-(2-(diphenylmethoxy)ethyl)-4-(2-(4-azido-3-iodophenyl)ethyl)piperazine binds to Slc6a3 protein |
RGD |
PMID:15763134 |
RGD:1625661 |
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
1-iodo-2,4-dinitrobenzene results in increased expression of ICAM1 protein |
CTD |
PMID:19427879 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases phosphorylation |
ISO |
1-iodo-2,4-dinitrobenzene results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:19427879 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression |
ISO |
1-iodo-2,4-dinitrobenzene results in increased expression of NFE2L2 protein |
CTD |
PMID:19427879 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases activity |
ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of ABCB1 protein |
CTD |
PMID:23273999 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases activity |
ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of ABCG2 protein |
CTD |
PMID:30083819 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions increases response to substance |
ISO |
ADCYAP1 gene mutant form promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein] ADCYAP1 gene mutant form results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine |
CTD |
PMID:24586556 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of AIFM1 protein |
CTD |
PMID:22983118 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
ISO |
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of BDNF mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of BDNF mRNA] |
CTD |
PMID:24889602 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Casp3 |
caspase 3 |
increases activity |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of CASP3 protein |
CTD |
PMID:22983118 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of CASP8 protein |
CTD |
PMID:22983118 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine affects the localization of CYCS protein |
CTD |
PMID:22983118 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR1 mRNA [Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of EGR1 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR1 mRNA] |
CTD |
PMID:24889602 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
increases expression multiple interactions |
ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR2 protein Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR2 protein]]; Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR2 protein] |
CTD |
PMID:32980479 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein ADCYAP1 gene mutant form promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein]; Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein]]; Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein] |
CTD |
PMID:12482207 PMID:24586556 PMID:32980479 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
increases activity multiple interactions |
ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI1 protein Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI1 protein]; Sirolimus inhibits the reaction [Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI1 protein]] |
CTD |
PMID:29748632 |
|
NCBI chr 4:16,813,941...16,898,111
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
increases activity multiple interactions |
ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI3 protein Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI3 protein]; Sirolimus inhibits the reaction [Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI3 protein]] |
CTD |
PMID:29748632 |
|
NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gnao1 |
G protein subunit alpha o1 |
multiple interactions |
ISO |
[Dronabinol results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased activity of GNAO1 protein |
CTD |
PMID:29748632 |
|
NCBI chr19:11,034,874...11,192,502
Ensembl chr19:11,035,956...11,192,493
|
|
G |
Gnaz |
G protein subunit alpha z |
increases activity multiple interactions |
ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAZ protein Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAZ protein]; Sirolimus inhibits the reaction [Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAZ protein]] |
CTD |
PMID:29748632 |
|
NCBI chr20:13,643,473...13,694,240
Ensembl chr20:13,644,640...13,669,907
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions affects binding affects response to substance increases activity decreases response to substance increases response to substance |
ISO EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine inhibits the reaction [Ketanserin binds to HTR2A protein]; [Alprenolol co-treated with Cocaine] affects the reaction [HTR2A protein results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine]; [Yohimbine co-treated with Cocaine] affects the reaction [HTR2A protein results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine]; Cocaine inhibits the reaction [HTR2A protein results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] 4-iodo-2,5-dimethoxyphenylisopropylamine binds to HTR2A protein HTR2A protein affects the susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine 4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein; [4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine; Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]]; Streptozocin inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of HTR2A protein] HTR2A gene SNP results in decreased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine 1-(8-bromobenzo(1,2-b;4,5-b')difuran-4-yl)-2-aminopropane inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine binds to HTR2A protein]; 4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein |
CTD |
PMID:8392199 PMID:9857084 PMID:10773215 PMID:12482207 PMID:16314884 PMID:18622176 PMID:22983118 PMID:29748632 More...
|
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
multiple interactions affects binding |
ISO |
1-(8-bromobenzo(1,2-b;4,5-b')difuran-4-yl)-2-aminopropane inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine binds to HTR2C protein] |
CTD |
PMID:9857084 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of IL1B protein 4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of and results in increased secretion of IL1B protein; gastrodin inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of IL1B protein]; rhyncophylline inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of and results in increased secretion of IL1B protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of and results in increased secretion of IL1B protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of IL1B protein] |
CTD |
PMID:30790395 PMID:31231976 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of IL6 protein 4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of and results in increased secretion of IL6 protein; gastrodin inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of IL6 protein]; rhyncophylline inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of and results in increased secretion of IL6 protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of and results in increased secretion of IL6 protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of IL6 protein] |
CTD |
PMID:30790395 PMID:31231976 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jak2 |
Janus kinase 2 |
increases phosphorylation multiple interactions |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of JAK2 protein rhyncophylline inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of JAK2 protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of JAK2 protein] |
CTD |
PMID:31231976 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of MAPK1 protein Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:30790395 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of MAPK3 protein Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:30790395 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of MAPK8 protein gastrodin inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of MAPK8 protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:30790395 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions increases expression |
EXP |
gastrodin inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of MYD88 protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of MYD88 protein] |
CTD |
PMID:30790395 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of NFKBIA protein rhyncophylline inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of NFKBIA protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:31231976 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos1 |
nitric oxide synthase 1 |
increases expression |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of NOS1 protein |
CTD |
PMID:12482207 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Pdyn |
prodynorphin |
decreases expression |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in decreased expression of PDYN mRNA |
CTD |
PMID:9526047 |
|
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
increases phosphorylation |
ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of PPP1R1B protein |
CTD |
PMID:11880652 |
|
NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of PTGS2 mRNA [Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of PTGS2 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of PTGS2 mRNA] |
CTD |
PMID:24889602 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation multiple interactions |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of RELA protein gastrodin inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of RELA protein]; rhyncophylline inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of RELA protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of RELA protein] |
CTD |
PMID:30790395 PMID:31231976 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions increases phosphorylation |
EXP |
rhyncophylline inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of STAT3 protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31231976 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression multiple interactions |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of TLR4 protein gastrodin inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of TLR4 protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of TLR4 protein] |
CTD |
PMID:30790395 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of and results in increased secretion of TNF protein; gastrodin inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of TNF protein]; rhyncophylline inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of and results in increased secretion of TNF protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of and results in increased secretion of TNF protein]; Tiapride Hydrochloride inhibits the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of TNF protein] |
CTD |
PMID:30790395 PMID:31231976 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases activity |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of BCL2 protein] |
CTD |
PMID:16135673 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
multiple interactions increases metabolic processing |
ISO |
[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine] |
CTD |
PMID:21565810 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions decreases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]] |
CTD |
PMID:26004626 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Triiodothyronine, Reverse promotes the reaction [THRA protein binds to NCOA2 protein]; Triiodothyronine, Reverse promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]]; Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:16135673 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
EXP |
Triiodothyronine, Reverse results in increased phosphorylation of NFKBIA protein alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:16135673 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions increases expression |
EXP |
Melatonin inhibits the reaction [Triiodothyronine, Reverse results in increased expression of NPPB mRNA]; Vitamin E affects the reaction [Triiodothyronine, Reverse results in increased expression of NPPB mRNA] |
CTD |
PMID:17198541 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions affects binding |
EXP |
2,4-dichlorophenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; 4-nonylphenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; 4-octylphenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; bisphenol A inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; Pentachlorophenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; tetrachlorodian inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein] |
CTD |
PMID:16617682 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
EXP |
Triiodothyronine, Reverse results in decreased expression of PPARA mRNA |
CTD |
PMID:17198541 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]]; Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:16135673 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SLC2A4 mRNA]; Vitamin E affects the reaction [Triiodothyronine, Reverse results in decreased expression of SLC2A4 mRNA] |
CTD |
PMID:17198541 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein]; Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SOD1 mRNA]; Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein; Vitamin E inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein]; Vitamin E inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SOD1 mRNA] |
CTD |
PMID:17198541 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased expression of and results in increased activity of SOD2 protein]; Triiodothyronine, Reverse results in increased expression of and results in increased activity of SOD2 protein |
CTD |
PMID:16135673 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO |
Triiodothyronine, Reverse inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol] |
CTD |
PMID:15531517 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Triiodothyronine, Reverse promotes the reaction [THRA protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
increases activity multiple interactions affects binding |
ISO |
Triiodothyronine, Reverse results in increased activity of THRB protein Triiodothyronine, Reverse promotes the reaction [THRB protein binds to NCOA2 protein] Triiodothyronine, Reverse binds to THRB protein |
CTD |
PMID:21543282 PMID:31566444 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased secretion of TNF protein] |
CTD |
PMID:16135673 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases activity |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of BCL2 protein] |
CTD |
PMID:16135673 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
multiple interactions increases metabolic processing |
ISO |
[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine] |
CTD |
PMID:21565810 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions decreases activity |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]] |
CTD |
PMID:26004626 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Triiodothyronine, Reverse promotes the reaction [THRA protein binds to NCOA2 protein]; Triiodothyronine, Reverse promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]]; Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:16135673 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
EXP |
Triiodothyronine, Reverse results in increased phosphorylation of NFKBIA protein alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:16135673 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions increases expression |
EXP |
Melatonin inhibits the reaction [Triiodothyronine, Reverse results in increased expression of NPPB mRNA]; Vitamin E affects the reaction [Triiodothyronine, Reverse results in increased expression of NPPB mRNA] |
CTD |
PMID:17198541 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions affects binding |
EXP |
2,4-dichlorophenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; 4-nonylphenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; 4-octylphenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; bisphenol A inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; Pentachlorophenol inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein]; tetrachlorodian inhibits the reaction [Triiodothyronine, Reverse binds to P4HB protein] |
CTD |
PMID:16617682 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression |
EXP |
Triiodothyronine, Reverse results in decreased expression of PPARA mRNA |
CTD |
PMID:17198541 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein]]; Triiodothyronine, Reverse results in increased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:16135673 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SLC2A4 mRNA]; Vitamin E affects the reaction [Triiodothyronine, Reverse results in decreased expression of SLC2A4 mRNA] |
CTD |
PMID:17198541 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein]; Melatonin inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SOD1 mRNA]; Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein; Vitamin E inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of and results in decreased expression of SOD1 protein]; Vitamin E inhibits the reaction [Triiodothyronine, Reverse results in decreased expression of SOD1 mRNA] |
CTD |
PMID:17198541 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased expression of and results in increased activity of SOD2 protein]; Triiodothyronine, Reverse results in increased expression of and results in increased activity of SOD2 protein |
CTD |
PMID:16135673 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO |
Triiodothyronine, Reverse inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol] |
CTD |
PMID:15531517 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Triiodothyronine, Reverse promotes the reaction [THRA protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
increases activity multiple interactions affects binding |
ISO |
Triiodothyronine, Reverse results in increased activity of THRB protein Triiodothyronine, Reverse promotes the reaction [THRB protein binds to NCOA2 protein] Triiodothyronine, Reverse binds to THRB protein |
CTD |
PMID:21543282 PMID:31566444 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
EXP |
alpha-Tocopherol inhibits the reaction [Triiodothyronine, Reverse results in increased secretion of TNF protein] 3,3',5-triiodothyronine increases expression of Tnf protein in serum |
CTD RGD |
PMID:16135673 PMID:15019085 |
RGD:14995431 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
tetraiodothyroacetic acid inhibits the reaction [Thyroxine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine results in increased phosphorylation of and results in increased activity of MAPK1 protein] tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK1 protein] |
CTD |
PMID:17174366 PMID:17984113 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
tetraiodothyroacetic acid inhibits the reaction [Thyroxine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine results in increased phosphorylation of and results in increased activity of MAPK3 protein] tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of MAPK3 protein] |
CTD |
PMID:17174366 PMID:17984113 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
tetraiodothyroacetic acid promotes the reaction [THRA protein binds to NCOA2 protein]; tetraiodothyroacetic acid promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]] |
CTD |
PMID:22227104 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]] |
CTD |
PMID:22227104 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
tetraiodothyroacetic acid binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
tetraiodothyroacetic acid binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
tetraiodothyroacetic acid binds to RXRA protein |
CTD |
PMID:31566444 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
tetraiodothyroacetic acid binds to and results in increased activity of THRA protein; tetraiodothyroacetic acid promotes the reaction [THRA protein binds to NCOA2 protein] |
CTD |
PMID:31566444 PMID:33049310 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions affects binding increases activity |
ISO |
tetraiodothyroacetic acid binds to and results in increased activity of THRB protein; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Thyroxine inhibits the reaction [THRB protein binds to NCOR2 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; tetraiodothyroacetic acid promotes the reaction [THRB protein binds to NCOA2 protein] tetraiodothyroacetic acid binds to THRB protein tetraiodothyroacetic acid results in increased activity of THRB protein |
CTD |
PMID:22227104 PMID:31077750 PMID:31566444 PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
tetraiodothyroacetic acid inhibits the reaction [Thyroxine affects the localization of TP53 protein modified form] |
CTD |
PMID:17984113 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ABCA1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in decreased activity of ABCB11 protein Triiodothyronine results in increased expression of ABCB11 mRNA [BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCB11 mRNA |
CTD |
PMID:28437613 PMID:34902352 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Triiodothyronine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ABCC5 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcf3 |
ATP binding cassette subfamily F member 3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ABCF3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr11:80,340,476...80,352,211
Ensembl chr11:80,339,977...80,352,211
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of ABCG5 mRNA [BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG5 mRNA |
CTD |
PMID:34902352 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of ABCG8 mRNA [BMS201038 co-treated with Triiodothyronine] results in increased expression of ABCG8 mRNA |
CTD |
PMID:34902352 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases expression increases activity |
EXP ISO |
Triiodothyronine inhibits the reaction [Streptozocin results in decreased activity of ACACA protein]; Triiodothyronine inhibits the reaction [Streptozocin results in decreased expression of ACACA mRNA] [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] Triiodothyronine results in increased expression of ACACA mRNA Triiodothyronine results in increased activity of ACACA protein |
CTD |
PMID:1973097 PMID:33476690 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acbd4 |
acyl-CoA binding domain containing 4 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ACBD4 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:88,048,058...88,062,612
Ensembl chr10:88,048,108...88,058,500
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
Triiodothyronine results in increased expression of and results in increased activity of ACE protein |
CTD |
PMID:1659346 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression decreases expression |
EXP |
Triiodothyronine results in increased expression of ACOT1 mRNA Triiodothyronine results in decreased expression of ACOT1 mRNA |
CTD |
PMID:15953391 PMID:28299817 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions increases expression |
EXP |
[BMS201038 co-treated with Triiodothyronine] results in increased expression of ACOX1 mRNA Triiodothyronine results in increased expression of ACOX1 mRNA |
CTD |
PMID:34902352 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ACSL1 mRNA |
CTD |
PMID:30209975 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ACSL5 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acvrl1 |
activin A receptor like type 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ACVRL1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591
|
|
G |
Adam11 |
ADAM metallopeptidase domain 11 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ADAM11 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:87,724,115...87,742,773
Ensembl chr10:87,724,234...87,741,562
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ADAM12 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ADAM15 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:174,754,631...174,765,136
Ensembl chr 2:174,754,633...174,765,113
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ADAM19 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Add2 |
adducin 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ADD2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:118,444,594...118,538,505
Ensembl chr 4:118,497,416...118,538,505
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein] |
CTD |
PMID:33476690 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ADRB1 mRNA; Triiodothyronine results in increased expression of ADRB1 protein |
CTD |
PMID:10217540 PMID:11090638 |
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases expression |
ISO |
bicalutamide inhibits the reaction [Triiodothyronine results in increased expression of ADRB2 protein] Triiodothyronine results in increased expression of ADRB2 mRNA; Triiodothyronine results in increased expression of ADRB2 protein |
CTD |
PMID:18454446 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions increases expression decreases expression |
EXP |
Amiodarone inhibits the reaction [Triiodothyronine results in decreased expression of ADRB3 protein] Triiodothyronine results in increased expression of ADRB3 protein Triiodothyronine results in decreased expression of ADRB3 mRNA; Triiodothyronine results in decreased expression of ADRB3 protein |
CTD |
PMID:8836703 PMID:10217540 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA] |
CTD |
PMID:28478156 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKAP12 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akirin2 |
akirin 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKIRIN2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 5:49,108,231...49,122,566
Ensembl chr 5:49,108,220...49,122,568
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKR1C1 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKR1C2 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AKR1C3 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine results in increased phosphorylation of AKT1 protein]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA] |
CTD |
PMID:16021636 PMID:18096819 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Triiodothyronine binds to ALB protein |
CTD |
PMID:21517007 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Amh |
anti-Mullerian hormone |
multiple interactions |
EXP |
Triiodothyronine affects the reaction [Propylthiouracil affects the expression of AMH mRNA] |
CTD |
PMID:7819453 |
|
NCBI chr 7:8,906,776...8,909,184
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Angptl8 |
angiopoietin-like 8 |
multiple interactions |
ISO |
[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:24262987 |
|
NCBI chr 8:20,376,462...20,378,488
Ensembl chr 8:20,376,462...20,378,490
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of APOA1 protein |
CTD |
PMID:6816881 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa4 |
apolipoprotein A4 |
multiple interactions |
EXP |
Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein] |
CTD |
PMID:6816881 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
EXP |
Triiodothyronine results in increased expression of [APOE protein co-treated with APOA4 protein] |
CTD |
PMID:6816881 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
decreases expression multiple interactions |
ISO |
Triiodothyronine results in decreased expression of APP mRNA; Triiodothyronine results in decreased expression of APP protein Tretinoin promotes the reaction [Triiodothyronine results in decreased secretion of APP protein] |
CTD |
PMID:17199430 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of AQP1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp8 |
aquaporin 8 |
increases expression |
EXP |
Triiodothyronine results in increased expression of AQP8 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Triiodothyronine inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgef25 |
Rho guanine nucleotide exchange factor 25 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ARHGEF25 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:63,005,938...63,013,325
Ensembl chr 7:63,005,940...63,013,719
|
|
G |
Arl4d |
ADP-ribosylation factor like GTPase 4D |
increases expression |
ISO |
Triiodothyronine results in increased expression of ARL4D mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:86,592,054...86,602,843
Ensembl chr10:86,595,661...86,602,836
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ARRDC3 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 2:11,137,443...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Aspg |
asparaginase |
increases expression |
EXP |
Triiodothyronine results in increased expression of ASPG mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268
|
|
G |
Aspm |
assembly factor for spindle microtubules |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ASPM mRNA |
CTD |
PMID:23397585 |
|
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
|
|
G |
Atg5 |
autophagy related 5 |
increases expression affects response to substance |
ISO |
Triiodothyronine results in increased expression of ATG5 mRNA; Triiodothyronine results in increased expression of ATG5 protein ATG5 protein affects the susceptibility to Triiodothyronine |
CTD |
PMID:30209975 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ATG7 mRNA |
CTD |
PMID:30209975 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ATP1B2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:54,318,698...54,324,933
Ensembl chr10:54,318,701...54,324,933
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions increases expression |
EXP |
THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of ATP2A2 mRNA] |
CTD |
PMID:11577024 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA] |
CTD |
PMID:11742803 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases expression |
ISO EXP |
Triiodothyronine results in decreased expression of BAD protein |
CTD |
PMID:16021636 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO EXP |
Triiodothyronine results in decreased expression of BAX protein |
CTD |
PMID:16021636 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
Triiodothyronine promotes the reaction [tamibarotene results in decreased expression of BCL2 mRNA] Triiodothyronine results in increased expression of BCL2 protein |
CTD |
PMID:11201846 PMID:16021636 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [tamibarotene results in increased expression of BCL2A1A mRNA] |
CTD |
PMID:11201846 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
ISO EXP |
Triiodothyronine results in increased expression of BCL2L1 protein |
CTD |
PMID:16021636 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
increases expression |
EXP |
Triiodothyronine results in increased expression of BCL3 mRNA |
CTD |
PMID:22015988 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of BMP2 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions decreases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of BMP6 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr17:26,318,121...26,469,034
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Capns1 |
calpain, small subunit 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CAPNS1 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions |
EXP ISO |
Triiodothyronine results in decreased expression of CASP3 protein THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA] |
CTD |
PMID:16021636 PMID:32223187 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein; gadolinium chloride inhibits the reaction [[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [Triiodothyronine results in decreased activity of CAT protein] |
CTD |
PMID:12516873 PMID:23391542 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc71 |
coiled-coil domain containing 71 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of CCDC71 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 8:109,146,650...109,161,749
Ensembl chr 8:109,146,359...109,165,216
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of CCL5 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CCL5 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccna2 |
cyclin A2 |
increases expression |
ISO EXP |
Triiodothyronine results in increased expression of CCNA2 protein |
CTD |
PMID:16021636 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in increased expression of CCND1 protein Triiodothyronine results in increased expression of CCND1 mRNA; Triiodothyronine results in increased expression of CCND1 protein THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of CCND1 mRNA] |
CTD |
PMID:16021636 PMID:20638743 PMID:28315333 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO EXP |
Triiodothyronine results in increased expression of CCNE1 protein Triiodothyronine results in increased expression of CCNE1 mRNA; Triiodothyronine results in increased expression of CCNE1 protein |
CTD |
PMID:16021636 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdc45 |
cell division cycle 45 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CDC45 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDKN1A mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of CDKN1A mRNA]; Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein] |
CTD |
PMID:14761676 PMID:22383522 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression multiple interactions |
EXP ISO |
Triiodothyronine results in decreased expression of CDKN1B mRNA; Triiodothyronine results in decreased expression of CDKN1B protein THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein] |
CTD |
PMID:16021636 PMID:20638743 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:33476690 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Ces2c |
carboxylesterase 2C |
increases expression |
EXP |
Triiodothyronine results in increased expression of CES2C mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions decreases expression |
EXP |
Phenelzine inhibits the reaction [Triiodothyronine results in decreased expression of CGA mRNA]; Triiodothyronine inhibits the reaction [Phenelzine results in increased expression of CGA mRNA] |
CTD |
PMID:20148560 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases phosphorylation |
ISO |
Triiodothyronine analog results in increased phosphorylation of CHEK1 protein |
CTD |
PMID:22383522 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chst1 |
carbohydrate sulfotransferase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of CHST1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:78,552,059...78,574,736
Ensembl chr 3:78,548,525...78,574,883
|
|
G |
Clu |
clusterin |
increases expression |
EXP |
Triiodothyronine results in increased expression of CLU mRNA |
CTD |
PMID:7531505 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions increases expression |
EXP |
ciglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA]; troglitazone inhibits the reaction [Triiodothyronine results in increased expression of COL10A1 mRNA] |
CTD |
PMID:16023420 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
EXP |
Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] Triiodothyronine results in increased expression of COL1A1 mRNA |
CTD |
PMID:18031379 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
increases expression |
ISO |
Triiodothyronine results in increased expression of COL6A3 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Coq10b |
coenzyme Q10B |
increases expression |
EXP |
Triiodothyronine results in increased expression of COQ10B mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 9:56,553,751...56,573,671
Ensembl chr 9:56,553,758...56,573,663
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
multiple interactions increases expression |
ISO |
Chloroquine promotes the reaction [Triiodothyronine results in increased expression of COX4I1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in increased expression of CPT1A mRNA Triiodothyronine results in increased expression of CPT1A mRNA; Triiodothyronine results in increased expression of CPT1A protein resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA] [BMS201038 co-treated with Triiodothyronine] results in increased expression of CPT1A mRNA; Resveratrol promotes the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of CPT1A mRNA] |
CTD |
PMID:23209300 PMID:25048947 PMID:34902352 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
increases expression |
ISO |
Triiodothyronine results in increased expression of CPT1B mRNA |
CTD |
PMID:30209975 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cracr2b |
calcium release activated channel regulator 2B |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of CRACR2B mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:196,558,407...196,563,961
Ensembl chr 1:196,558,588...196,563,771
|
|
G |
Crat |
carnitine O-acetyltransferase |
increases expression |
EXP |
Triiodothyronine results in increased expression of CRAT mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
increases expression |
EXP |
Triiodothyronine results in increased expression of CSAD mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615
|
|
G |
Csk |
C-terminal Src kinase |
multiple interactions |
ISO |
CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]] |
CTD |
PMID:9664232 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Ctse |
cathepsin E |
increases expression |
EXP |
Triiodothyronine results in increased expression of CTSE mRNA |
CTD |
PMID:15953391 |
|
NCBI chr13:43,091,954...43,114,509
Ensembl chr13:43,092,128...43,114,502
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA] |
CTD |
PMID:32223187 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein] |
CTD |
PMID:21726595 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein] |
CTD |
PMID:21726595 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Triiodothyronine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:28478156 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of CYP1A2 mRNA Triiodothyronine affects the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]; Triiodothyronine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 protein] |
CTD |
PMID:28478156 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of CYP24A1 mRNA (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of CYP24A1 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases activity increases expression |
EXP |
Triiodothyronine results in increased activity of CYP2E1 protein Triiodothyronine results in increased expression of CYP2E1 protein |
CTD |
PMID:14631868 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of CYP3A4 mRNA SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:10393316 PMID:29357290 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
increases expression |
ISO |
Triiodothyronine results in increased expression of DBP mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Decr2 |
2,4-dienoyl-CoA reductase 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of DECR2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
affects abundance multiple interactions increases expression affects metabolic processing increases chemical synthesis |
ISO EXP |
DIO1 gene SNP affects the abundance of Triiodothyronine 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA] [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Thyroxine] which results in increased abundance of Triiodothyronine] DIO1 protein affects the metabolism of Triiodothyronine Arsenic affects the reaction [Triiodothyronine results in increased expression of DIO1 mRNA]; Pentachlorophenol inhibits the reaction [Triiodothyronine results in increased expression of DIO1 mRNA] DIO1 protein results in increased chemical synthesis of Triiodothyronine |
CTD |
PMID:15254343 PMID:16131326 PMID:17105838 PMID:18288313 PMID:21565810 PMID:23397585 PMID:24001430 PMID:25646720 PMID:27420076 PMID:28167136 PMID:29357290 More...
|
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions increases expression increases chemical synthesis |
ISO EXP |
2,2',4,4',5-brominated diphenyl ether inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4',5-brominated diphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [[DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine]; [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine; [DIO2 protein results in increased metabolism of Thyroxine] which results in increased chemical synthesis of Triiodothyronine; kaempferol promotes the reaction [DIO2 protein results in increased activity of and results in increased abundance of Triiodothyronine] Triiodothyronine results in increased expression of DIO2 mRNA DIO2 protein results in increased chemical synthesis of Triiodothyronine |
CTD |
PMID:17327447 PMID:17615150 PMID:23397585 PMID:25646720 PMID:26004626 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of DIO3 mRNA [DIO1 protein co-treated with DIO2 protein co-treated with DIO3 protein] affects the abundance of Triiodothyronine |
CTD |
PMID:23397585 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dmbt1 |
deleted in malignant brain tumors 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DMBT1 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:185,617,469...185,696,476
Ensembl chr 1:185,617,294...185,696,478
|
|
G |
Dmpk |
DM1 protein kinase |
increases expression |
EXP |
Triiodothyronine results in increased expression of DMPK mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593
|
|
G |
Dmtn |
dematin actin binding protein |
increases expression |
ISO |
Triiodothyronine results in increased expression of DMTN mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:45,677,974...45,705,601
Ensembl chr15:45,677,977...45,705,601
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
multiple interactions decreases expression |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of DUSP2 mRNA; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in decreased expression of DUSP2 mRNA] |
CTD |
PMID:14761676 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Dync1li2 |
dynein, cytoplasmic 1 light intermediate chain 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of DYNC1LI2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr19:531,783...554,670
Ensembl chr19:531,812...554,670
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ECH1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Efcab3 |
EF-hand calcium binding domain 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of EFCAB3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:89,583,526...90,077,260
Ensembl chr10:89,644,522...90,077,259
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP ISO |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA] Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11742803 PMID:16150908 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation |
ISO |
Triiodothyronine results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:30209975 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eml2 |
EMAP like 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of EML2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 1:78,827,595...78,859,343
Ensembl chr 1:78,828,080...78,859,341
|
|
G |
Eno1 |
enolase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ENO1 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of EPAS1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 6:7,790,236...7,871,246
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of EPB41L3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Triiodothyronine results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
Tamoxifen inhibits the reaction [Triiodothyronine results in decreased expression of ESR1 mRNA]; Triiodothyronine binds to and results in increased activity of ESR1 protein |
CTD |
PMID:19942988 PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
EXP ISO |
[Arsenic co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of ESR2 mRNA; [bisphenol A co-treated with Zearalenone co-treated with Arsenic co-treated with enzacamene co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [bisphenol A results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in increased expression of ESR2 mRNA; [enzacamene co-treated with Estradiol co-treated with Triiodothyronine] affects the expression of ESR2 mRNA; [Estradiol co-treated with Triiodothyronine] inhibits the reaction [bisphenol A results in decreased expression of ESR2 mRNA]; [Estradiol co-treated with Triiodothyronine] promotes the reaction [Zearalenone results in decreased expression of ESR2 mRNA]; [Zearalenone co-treated with Estradiol co-treated with Triiodothyronine] results in decreased expression of ESR2 mRNA; [Zearalenone results in increased susceptibility to [Estradiol co-treated with Triiodothyronine]] which results in decreased expression of ESR2 mRNA Triiodothyronine binds to and results in increased activity of ESR2 protein |
CTD |
PMID:27338438 PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Ethe1 |
ETHE1, persulfide dioxygenase |
increases expression |
EXP |
Triiodothyronine results in increased expression of ETHE1 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 1:80,184,037...80,199,092
Ensembl chr 1:80,183,894...80,199,052
|
|
G |
Eva1c |
eva-1 homolog C |
increases expression |
ISO |
Triiodothyronine results in increased expression of EVA1C mRNA |
CTD |
PMID:25172293 |
|
NCBI chr11:30,089,510...30,163,596
Ensembl chr11:30,089,365...30,163,596
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of FABP4 mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA] |
CTD |
PMID:15953391 PMID:33476690 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FABP5 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Fads2 |
fatty acid desaturase 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FADS2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fam171b |
family with sequence similarity 171, member B |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of FAM171B mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 3:68,930,755...68,986,113
Ensembl chr 3:68,930,822...68,986,127
|
|
G |
Fam83h |
family with sequence similarity 83, member H |
increases expression |
ISO |
Triiodothyronine results in increased expression of FAM83H mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:107,716,431...107,724,619
Ensembl chr 7:107,716,431...107,728,672
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of FASN mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA] |
CTD |
PMID:15953391 PMID:33476690 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FDFT1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
increases expression |
EXP |
Triiodothyronine results in increased expression of FDPS mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA] |
CTD |
PMID:11742803 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16150908 |
|
NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO EXP |
Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein] [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:11742803 PMID:12805413 PMID:16150908 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of FGF7 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16150908 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
increases expression multiple interactions |
ISO EXP |
Triiodothyronine results in increased expression of FGFR1 mRNA Triiodothyronine results in increased expression of FGFR1 mRNA; Triiodothyronine results in increased expression of FGFR1 protein Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Dactinomycin inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein promotes the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]] |
CTD |
PMID:12805413 PMID:16150908 |
|
NCBI chr16:66,492,445...66,546,731
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FGFR2 mRNA |
CTD |
PMID:16150908 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FGFR3 mRNA |
CTD |
PMID:16150908 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fkbp10 |
FKBP prolyl isomerase 10 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of FKBP10 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330
|
|
G |
Flrt1 |
fibronectin leucine rich transmembrane protein 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FLRT1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:204,275,785...204,292,844
Ensembl chr 1:204,275,367...204,353,750
|
|
G |
Foxo6 |
forkhead box O6 |
increases expression |
ISO |
Triiodothyronine results in increased expression of FOXO6 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:133,856,800...133,875,922
Ensembl chr 5:133,856,072...133,876,573
|
|
G |
Fpgs |
folylpolyglutamate synthase |
increases expression |
EXP |
Triiodothyronine results in increased expression of FPGS mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:15,972,800...15,993,592
Ensembl chr 3:15,972,800...15,993,563
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA] |
CTD |
PMID:7531505 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of FXYD2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 8:45,712,887...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions increases expression |
ISO |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of G6PC1 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GAP43 mRNA; Triiodothyronine results in increased expression of GAP43 protein |
CTD |
PMID:15708448 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gba |
glucosylceramidase beta |
increases activity |
EXP |
Triiodothyronine results in increased activity of GBA protein |
CTD |
PMID:9101438 |
|
NCBI chr 2:174,609,437...174,615,457
Ensembl chr 2:174,609,403...174,618,263
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GCH1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions increases expression |
EXP ISO |
Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Amiodarone inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; bisphenol A promotes the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Dexamethasone promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Edetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]; Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Polybrominated Biphenyls analog inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]; Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]; Triiodothyronine results in increased expression of and results in increased secretion of GH protein; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Alitretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Tretinoin promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Alitretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine promotes the reaction [Tretinoin results in increased expression of GH1 mRNA]]]; Zinc inhibits the reaction [Pentetic Acid promotes the reaction [Triiodothyronine results in increased expression of GH1 mRNA]] Triiodothyronine results in increased expression of GH mRNA; Triiodothyronine results in increased expression of GH1 mRNA; Triiodothyronine results in increased expression of GH1 protein |
CTD |
PMID:2211641 PMID:2910914 PMID:10720163 PMID:15240998 PMID:17090972 PMID:17928132 PMID:22201216 PMID:24001430 PMID:27420076 More...
|
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Ghrh |
growth hormone releasing hormone |
multiple interactions |
EXP |
Triiodothyronine promotes the reaction [Dexamethasone results in increased expression of GHRH mRNA] |
CTD |
PMID:17090972 |
|
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GJA1 protein |
CTD |
PMID:15685554 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GPCPD1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:119,787,681...119,832,550
Ensembl chr 3:119,787,682...119,832,517
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of GPD2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [BMS201038 results in increased expression of GPT protein] |
CTD |
PMID:34902352 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Grik4 |
glutamate ionotropic receptor kainate type subunit 4 |
increases expression |
ISO |
Triiodothyronine results in increased expression of GRIK4 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTA2 protein] |
CTD |
PMID:7532609 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
EXP |
Triiodothyronine inhibits the reaction [goitrin results in increased expression of GSTP1 protein] |
CTD |
PMID:7532609 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstp3 |
glutathione S-transferase pi 3 |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of RGD1307603 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 1:201,355,682...201,358,330
Ensembl chr 1:201,355,682...201,358,330
|
|
G |
Gulp1 |
GULP PTB domain containing engulfment adaptor 1 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of GULP1 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005
|
|
G |
H1f5 |
H1.5 linker histone, cluster member |
increases expression |
ISO |
Triiodothyronine results in increased expression of H1-5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr17:42,726,189...42,726,857
Ensembl chr17:42,726,127...42,769,160
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions |
ISO |
Triiodothyronine analog results in increased phosphorylation of H2AX protein Triiodothyronine analog promotes the reaction [Cisplatin results in increased expression of H2AX protein] |
CTD |
PMID:22383522 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hba-a1 |
hemoglobin alpha, adult chain 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of HBA-A1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hbb |
hemoglobin subunit beta |
increases expression |
EXP |
Triiodothyronine results in increased expression of HBB mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hbg1 |
hemoglobin subunit gamma 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of HBG1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:158,271,993...158,273,371
Ensembl chr 1:158,271,873...158,273,425
|
|
G |
Hcn2 |
hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HCN2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 7:9,969,801...9,988,839
Ensembl chr 7:9,970,368...9,988,841
|
|
G |
Hdc |
histidine decarboxylase |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of HDC mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
|
|
G |
Heg1 |
heart development protein with EGF-like domains 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HEG1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr11:67,006,954...67,095,020
Ensembl chr11:66,957,190...67,095,051
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Triiodothyronine results in increased expression of HIF1A mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Higd1a |
HIG1 hypoxia inducible domain family, member 1A |
increases expression |
EXP |
Triiodothyronine results in increased expression of HIGD1A mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 8:121,514,152...121,523,382
Ensembl chr 8:121,514,156...121,523,443
|
|
G |
Hira |
histone cell cycle regulator |
increases expression |
ISO |
Triiodothyronine results in increased expression of HIRA mRNA |
CTD |
PMID:23397585 |
|
NCBI chr11:82,024,469...82,133,212
Ensembl chr11:82,024,469...82,133,529
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HMGCS2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hnrnph3 |
heterogeneous nuclear ribonucleoprotein H3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of HNRNPH3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr20:25,616,400...25,625,814
Ensembl chr20:25,614,733...25,625,750
|
|
G |
Hr |
HR, lysine demethylase and nuclear receptor corepressor |
increases expression |
ISO |
Triiodothyronine results in increased expression of HR mRNA |
CTD |
PMID:25172293 PMID:26096596 |
|
NCBI chr15:45,626,835...45,646,313
Ensembl chr15:45,626,835...45,646,313
|
|
G |
Hscb |
HscB mitochondrial iron-sulfur cluster co-chaperone |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of HSCB mRNA |
CTD |
PMID:23397585 |
|
NCBI chr12:45,821,527...45,831,902
Ensembl chr12:45,821,555...45,831,909
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:21726595 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hunk |
hormonally upregulated Neu-associated kinase |
increases expression |
ISO |
Triiodothyronine results in increased expression of HUNK mRNA |
CTD |
PMID:25172293 |
|
NCBI chr11:29,641,051...29,758,392
Ensembl chr11:29,640,775...29,757,526
|
|
G |
Idh1 |
isocitrate dehydrogenase (NADP(+)) 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of IDH1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 9:66,534,146...66,563,703
Ensembl chr 9:66,534,146...66,563,708
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases expression increases secretion |
EXP |
Estradiol inhibits the reaction [Triiodothyronine results in increased expression of IGF1 mRNA]; Estradiol inhibits the reaction [Triiodothyronine results in increased secretion of IGF1 protein] |
CTD |
PMID:7684602 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of IGFBP2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Iglon5 |
IgLON family member 5 |
increases expression |
ISO |
Triiodothyronine results in increased expression of IGLON5 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:93,880,906...93,898,929
Ensembl chr 1:93,881,991...93,898,754
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Triiodothyronine results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein] Triiodothyronine results in increased expression of IL1B mRNA |
CTD |
PMID:32223187 PMID:32816093 PMID:33476690 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Triiodothyronine results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein] |
CTD |
PMID:32223187 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhbb |
inhibin subunit beta B |
multiple interactions increases expression |
EXP |
FSHB protein promotes the reaction [Triiodothyronine results in increased expression of INHBB mRNA]; Triiodothyronine promotes the reaction [FSHB protein results in increased expression of INHBB mRNA] |
CTD |
PMID:7531505 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with Rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:27605626 PMID:33476690 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of INSIG1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of IRF1 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [tamibarotene results in increased expression of ITGAM protein] |
CTD |
PMID:11201846 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]] |
CTD |
PMID:22227104 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Itgb5 |
integrin subunit beta 5 |
increases expression decreases expression |
ISO |
Triiodothyronine results in increased expression of ITGB5 mRNA Triiodothyronine results in decreased expression of ITGB5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr11:66,828,428...66,944,231
Ensembl chr11:66,829,285...66,944,472
|
|
G |
Itpk1 |
inositol-tetrakisphosphate 1-kinase |
increases expression |
ISO |
Triiodothyronine results in increased expression of ITPK1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 6:121,710,750...121,844,501
Ensembl chr 6:121,710,755...121,844,107
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ITPR1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Kantr |
KANTR integral membrane protein |
increases expression |
ISO |
Triiodothyronine results in increased expression of KANTR mRNA |
CTD |
PMID:25172293 |
|
NCBI chr X:21,402,717...21,430,663
|
|
G |
Kcna1 |
potassium voltage-gated channel subfamily A member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of KCNA1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682
|
|
G |
Kcna4 |
potassium voltage-gated channel subfamily A member 4 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of KCNA4 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:93,756,399...93,778,004
Ensembl chr 3:93,756,446...93,769,162
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein |
CTD |
PMID:27605626 |
|
NCBI chr15:302,078...1,001,198
Ensembl chr15:302,214...1,001,198
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of KCTD12 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:79,800,077...79,806,064
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Kif1b |
kinesin family member 1B |
increases expression |
EXP |
Triiodothyronine results in increased expression of KIF1B mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Klf9 |
Kruppel-like factor 9 |
decreases expression increases expression |
ISO |
Triiodothyronine results in decreased expression of KLF9 mRNA Triiodothyronine results in increased expression of KLF9 mRNA |
CTD |
PMID:15507505 PMID:23397585 PMID:26096596 PMID:35172007 |
|
NCBI chr 1:220,700,108...220,725,029
Ensembl chr 1:220,700,108...220,725,037
|
|
G |
Krt13 |
keratin 13 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of KRT13 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr10:85,052,122...85,056,032
Ensembl chr10:85,051,889...85,056,084
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO EXP |
Amiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA]; desethylamiodarone promotes the reaction [Triiodothyronine results in increased expression of LDLR mRNA] Triiodothyronine inhibits the reaction [Amiodarone results in decreased expression of LDLR protein] |
CTD |
PMID:9071962 PMID:9712728 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lgi4 |
leucine-rich repeat LGI family, member 4 |
increases expression |
ISO |
Triiodothyronine results in increased expression of LGI4 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 1:86,294,539...86,305,909
Ensembl chr 1:86,295,074...86,304,874
|
|
G |
Lhx3 |
LIM homeobox 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of LHX3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 3:9,026,432...9,035,122
Ensembl chr 3:9,027,425...9,034,480
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases expression |
ISO |
Triiodothyronine results in increased expression of LIPE mRNA |
CTD |
PMID:30209975 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of LMCD1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046
|
|
G |
LOC120093420 |
small nucleolar RNA SNORA28 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of SNORA28 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 6:130,591,965...130,592,090
Ensembl chr 6:130,591,965...130,592,090
|
|
G |
Lpin3 |
lipin 3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of LPIN3 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
EXP |
Triiodothyronine results in increased expression of LPL mRNA |
CTD |
PMID:15953391 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lss |
lanosterol synthase |
increases expression |
EXP |
Triiodothyronine results in increased expression of LSS mRNA |
CTD |
PMID:15953391 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Ltb4r |
leukotriene B4 receptor |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of LTB4R mRNA |
CTD |
PMID:14761676 |
|
NCBI chr15:29,263,126...29,265,716
|
|
G |
Lyrm9 |
LYR motif containing 9 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of LYRM9 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:63,725,718...63,739,772
Ensembl chr10:63,725,743...63,739,772
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases lipidation increases expression multiple interactions |
ISO |
Triiodothyronine results in increased lipidation of MAP1LC3B protein Triiodothyronine results in increased expression of MAP1LC3B mRNA bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
ISO EXP |
tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Triiodothyronine results in increased phosphorylation of and results in increased activity of MAPK1 protein Triiodothyronine results in increased expression of MAPK1 mRNA Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK1 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK1 mRNA] |
CTD |
PMID:12805413 PMID:16150908 PMID:17174366 PMID:28315333 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression |
ISO EXP |
tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Triiodothyronine results in increased phosphorylation of and results in increased activity of MAPK3 protein Triiodothyronine results in increased expression of MAPK3 mRNA Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] Triiodothyronine inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF18 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF2 protein results in increased phosphorylation of MAPK3 protein]; Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MAPK3 mRNA] |
CTD |
PMID:12805413 PMID:16150908 PMID:17174366 PMID:28315333 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mbp |
myelin basic protein |
increases expression |
ISO |
Triiodothyronine results in increased expression of MBP protein alternative form |
CTD |
PMID:15345905 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of ME1 mRNA |
CTD |
PMID:15953391 PMID:29357290 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Meioc |
meiosis specific with coiled-coil domain |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of MEIOC mRNA |
CTD |
PMID:23397585 |
|
NCBI chr10:87,628,807...87,646,485
Ensembl chr10:87,628,875...87,646,752
|
|
G |
Mfsd2a |
major facilitator superfamily domain containing 2A |
increases expression |
ISO |
Triiodothyronine results in increased expression of MFSD2A mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
|
|
G |
Mier3 |
MIER family member 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of MIER3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:43,287,546...43,316,422
Ensembl chr 2:43,287,916...43,316,136
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of MKI67 mRNA U 0126 inhibits the reaction [Triiodothyronine results in increased expression of MKI67 mRNA] |
CTD |
PMID:28315333 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmd2 |
monocyte to macrophage differentiation-associated 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of MMD2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr12:11,962,733...12,009,776
Ensembl chr12:11,962,757...12,009,773
|
|
G |
Mmp11 |
matrix metallopeptidase 11 |
multiple interactions increases expression |
ISO |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of MMP11 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr20:12,730,846...12,739,629
Ensembl chr20:12,730,836...12,739,628
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP ISO |
Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein] [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA |
CTD |
PMID:18031379 PMID:33091441 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased activity of MPO protein |
CTD |
PMID:7503757 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
Triiodothyronine results in decreased phosphorylation of MTOR protein |
CTD |
PMID:30209975 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myh6 |
myosin heavy chain 6 |
multiple interactions increases expression |
EXP |
S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of MYH6 mRNA] |
CTD |
PMID:11577024 PMID:15578571 PMID:15652358 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions decreases expression |
EXP |
Triiodothyronine inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA] Triiodothyronine results in decreased expression of MYH7 mRNA |
CTD |
PMID:11577024 PMID:15578571 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Naglt1 |
Na+ dependent glucose transporter 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NAGLT1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr20:43,411,550...43,423,873
Ensembl chr20:43,394,843...43,423,873
|
|
G |
Ncapg2 |
non-SMC condensin II complex, subunit G2 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of NCAPG2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 6:137,342,449...137,418,083
Ensembl chr 6:137,342,943...137,415,159
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein] |
CTD |
PMID:22227104 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:29146198 PMID:31566444 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein] |
CTD |
PMID:22227104 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein] |
CTD |
PMID:22227104 |
|
NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319
|
|
G |
Ndufa5 |
NADH:ubiquinone oxidoreductase subunit A5 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NDUFA5 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598
|
|
G |
Nefl |
neurofilament light chain |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of NEFL mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of NEFM mRNA |
CTD |
PMID:25172293 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:33476690 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases activity multiple interactions |
EXP |
Triiodothyronine results in increased activity of NFKB1 protein Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of NFKB1 protein] |
CTD |
PMID:15019085 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA |
CTD |
PMID:33476690 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nnat |
neuronatin |
decreases expression |
EXP |
Triiodothyronine results in decreased expression of NNAT mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Npnt |
nephronectin |
increases expression |
ISO |
Triiodothyronine results in increased expression of NPNT mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:221,391,153...221,459,401
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NR0B2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Triiodothyronine binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:21726595 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nrgn |
neurogranin |
increases expression |
EXP |
Triiodothyronine results in increased expression of NRGN mRNA; Triiodothyronine results in increased expression of NRGN protein |
CTD |
PMID:15708448 |
|
NCBI chr 8:37,255,462...37,263,659
Ensembl chr 8:37,256,930...37,257,516
|
|
G |
Nrp1 |
neuropilin 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NRP1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
EXP |
Triiodothyronine results in increased expression of NSDHL mRNA |
CTD |
PMID:15953391 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Nsmf |
NMDA receptor synaptonuclear signaling and neuronal migration factor |
increases expression |
EXP |
Triiodothyronine results in increased expression of NSMF mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:7,861,846...7,870,615
Ensembl chr 3:7,861,872...7,870,614
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression increases activity |
EXP |
Triiodothyronine results in increased expression of NT5E mRNA Triiodothyronine results in increased activity of NT5E protein |
CTD |
PMID:15543949 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nudt7 |
nudix hydrolase 7 |
increases expression |
EXP |
Triiodothyronine results in increased expression of NUDT7 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr19:42,125,679...42,151,198
Ensembl chr19:42,125,711...42,151,081
|
|
G |
Nup214 |
nucleoporin 214 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of NUP214 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 3:15,255,111...15,340,568
Ensembl chr 3:15,255,119...15,340,568
|
|
G |
Ocln |
occludin |
increases expression |
EXP |
Triiodothyronine results in increased expression of OCLN mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Olr59 |
olfactory receptor 59 |
increases expression |
EXP |
Triiodothyronine results in increased expression of OLR59 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:157,193,080...157,211,179
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of OSGIN1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions affects binding |
EXP |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine binds to P4HB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to P4HB protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of and results in increased secretion of GH protein]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 mRNA]; P4HB protein inhibits the reaction [Triiodothyronine results in increased expression of GH1 protein]; Polychlorinated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to P4HB protein] |
CTD |
PMID:17928132 PMID:18515855 PMID:19374345 PMID:22201216 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Padi4 |
peptidyl arginine deiminase 4 |
increases expression |
EXP |
Triiodothyronine results in increased expression of PADI4 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:153,041,351...153,074,412
Ensembl chr 5:153,041,352...153,074,362
|
|
G |
Parp4 |
poly (ADP-ribose) polymerase family, member 4 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PARP4 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr15:30,690,503...30,792,868
Ensembl chr15:30,686,613...30,828,810
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions increases expression |
EXP ISO |
SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA] (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of PCK1 mRNA] |
CTD |
PMID:21815645 PMID:23209300 PMID:30209975 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression multiple interactions affects binding |
ISO |
Triiodothyronine results in increased expression of PCNA protein THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein] Triiodothyronine analog inhibits the reaction [CDKN1A protein binds to PCNA protein]; Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein]; Triiodothyronine inhibits the reaction [CDKN1A protein binds to PCNA protein] Triiodothyronine analog binds to PCNA protein; Triiodothyronine binds to PCNA protein |
CTD |
PMID:17174366 PMID:20638743 PMID:22383522 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcsk1 |
proprotein convertase subtilisin/kexin type 1 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PCSK1 mRNA |
CTD |
PMID:15291740 |
|
NCBI chr 2:4,395,543...4,442,434
Ensembl chr 2:4,395,543...4,442,434
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PCSK2 mRNA |
CTD |
PMID:15585599 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
multiple interactions increases expression |
ISO EXP |
resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA] resveratrol promotes the reaction [Triiodothyronine results in increased expression of PDK4 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA] |
CTD |
PMID:23209300 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdp2 |
pyruvate dehydrogenase phosphatase catalytic subunit 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of PDP2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr19:386,408...394,068
Ensembl chr19:386,406...394,074
|
|
G |
Peg10 |
paternally expressed 10 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PEG10 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:32,842,394...32,855,641
Ensembl chr 4:32,848,493...32,852,621
|
|
G |
Pex5 |
peroxisomal biogenesis factor 5 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PEX5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:157,270,671...157,296,432
Ensembl chr 4:157,270,672...157,296,431
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression |
ISO |
Triiodothyronine results in increased expression of PFKP mRNA |
CTD |
PMID:15507505 |
|
NCBI chr17:63,729,743...63,794,021
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Phospho1 |
phosphoethanolamine/phosphocholine phosphatase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PHOSPHO1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:80,762,062...80,769,596
Ensembl chr10:80,760,792...80,770,342
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
increases expression |
ISO |
Triiodothyronine results in increased expression of PIK3CD mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
increases expression |
EXP |
Triiodothyronine results in increased expression of PLA2G6 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114
|
|
G |
Pld5 |
phospholipase D family, member 5 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PLD5 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr13:87,895,694...88,232,868
Ensembl chr13:87,896,369...88,232,868
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of PLIN2 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:101,156,643...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Plin3 |
perilipin 3 |
multiple interactions |
ISO |
[THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein] |
CTD |
PMID:24262987 |
|
NCBI chr 9:1,111,178...1,123,117
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Plxnc1 |
plexin C1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PLXNC1 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PMP22 mRNA |
CTD |
PMID:29901742 |
|
NCBI chr10:47,795,709...47,825,715
Ensembl chr10:47,795,709...47,825,714
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
increases expression decreases phosphorylation |
ISO |
Triiodothyronine results in increased expression of PNPLA2 mRNA Triiodothyronine results in decreased phosphorylation of PNPLA2 protein |
CTD |
PMID:30209975 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Podxl |
podocalyxin-like |
increases expression |
EXP |
Triiodothyronine results in increased expression of PODXL mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
|
|
G |
Pold3 |
DNA polymerase delta 3, accessory subunit |
multiple interactions |
ISO |
Triiodothyronine analog inhibits the reaction [POLD3 protein binds to PCNA protein] |
CTD |
PMID:22383522 |
|
NCBI chr 1:154,417,893...154,456,687
Ensembl chr 1:154,418,084...154,456,665
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of POLG mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of POMT1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
[GW 7647 results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [pirinixic acid results in increased activity of PPARA protein] promotes the reaction [Phenobarbital results in increased degradation of Triiodothyronine]; [Triiodothyronine co-treated with Oleic Acid co-treated with Palmitic Acid] results in decreased expression of PPARA mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA] |
CTD |
PMID:19631232 PMID:25048947 PMID:33476690 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
Triiodothyronine inhibits the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of PPARG mRNA] [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Triiodothyronine binds to and results in increased activity of PPARG protein |
CTD |
PMID:25048947 PMID:33049310 PMID:33476690 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
EXP ISO |
Triiodothyronine results in increased expression of PPARGC1A mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA] [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein |
CTD |
PMID:23209300 PMID:30209975 PMID:33091441 PMID:33476690 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prdm16 |
PR/SET domain 16 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of PRDM16 mRNA [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA |
CTD |
PMID:30209975 PMID:33091441 |
|
NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601
|
|
G |
Prelp |
proline and arginine rich end leucine rich repeat protein |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PRELP mRNA |
CTD |
PMID:25172293 |
|
NCBI chr13:45,368,407...45,391,480
Ensembl chr13:45,370,533...45,380,270
|
|
G |
Prickle2 |
prickle planar cell polarity protein 2 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of PRICKLE2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:124,869,552...125,214,862
Ensembl chr 4:124,869,552...125,214,824
|
|
G |
Prl |
prolactin |
decreases expression increases secretion multiple interactions |
EXP |
Triiodothyronine results in decreased expression of PRL mRNA; Triiodothyronine results in decreased expression of PRL protein Triiodothyronine results in increased secretion of PRL protein bisphenol A inhibits the reaction [Triiodothyronine results in increased secretion of PRL protein]; Chlorodiphenyl (54% Chlorine) promotes the reaction [Triiodothyronine results in increased secretion of PRL protein] |
CTD |
PMID:3734668 PMID:17615682 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prokr1 |
prokineticin receptor 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PROKR1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 4:120,022,301...120,033,379
Ensembl chr 4:120,021,747...120,033,379
|
|
G |
Psca |
prostate stem cell antigen |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of PSCA protein] Triiodothyronine results in increased expression of PSCA mRNA; Triiodothyronine results in increased expression of PSCA protein |
CTD |
PMID:14761676 |
|
NCBI chr 7:106,598,203...106,603,114
Ensembl chr 7:106,595,284...106,609,746
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rab23 |
RAB23, member RAS oncogene family |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of RAB23 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 9:35,943,522...35,967,367
Ensembl chr 9:35,944,085...35,966,927
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
increases expression |
ISO |
Triiodothyronine results in increased expression of RAB3B mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Rarb |
retinoic acid receptor, beta |
increases expression |
EXP |
Triiodothyronine results in increased expression of RARB mRNA |
CTD |
PMID:15708448 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases activity |
EXP |
Hexachlorocyclohexane affects the reaction [Triiodothyronine results in increased activity of RELA protein] |
CTD |
PMID:15019085 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Retsat |
retinol saturase |
increases expression |
EXP |
Triiodothyronine results in increased expression of RETSAT mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
|
|
G |
RGD1306063 |
similar to HT021 |
increases expression |
EXP |
Triiodothyronine results in increased expression of RGD1306063 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838
|
|
G |
RGD1564801 |
similar to hepatic multiple inositol polyphosphate phosphatase |
increases expression |
EXP |
Triiodothyronine results in increased expression of RGD1564801 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:74,017,248...74,019,633
Ensembl chr 1:230,354,438...230,379,730
|
|
G |
Rhov |
ras homolog family member V |
increases expression |
ISO |
Triiodothyronine results in increased expression of RHOV mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 3:106,260,774...106,270,009
Ensembl chr 3:106,260,776...106,269,479
|
|
G |
Rpa2 |
replication protein A2 |
increases phosphorylation |
ISO |
Triiodothyronine analog results in increased phosphorylation of RPA2 protein |
CTD |
PMID:22383522 |
|
NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Triiodothyronine results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rxrb |
retinoid X receptor beta |
increases expression |
EXP |
Triiodothyronine results in increased expression of RXRB mRNA |
CTD |
PMID:15708448 |
|
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
|
|
G |
Rxrg |
retinoid X receptor gamma |
increases expression |
EXP |
Triiodothyronine results in increased expression of RXRG mRNA |
CTD |
PMID:15708448 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
multiple interactions |
EXP |
S100A6 protein inhibits the reaction [Triiodothyronine results in increased expression of MYH6 mRNA] |
CTD |
PMID:15652358 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
EXP |
Triiodothyronine results in increased expression of SC5D mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
EXP |
Triiodothyronine results in increased expression of SCD1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpina6 |
serpin family A member 6 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SERPINA6 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 6:122,780,040...122,790,274
Ensembl chr 6:122,780,043...122,790,349
|
|
G |
Serpina7 |
serpin family A member 7 |
affects binding |
ISO |
Triiodothyronine binds to SERPINA7 protein |
CTD |
PMID:20804816 PMID:21517007 |
|
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
|
|
G |
Sigmar1 |
sigma non-opioid intracellular receptor 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SIGMAR1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases expression affects response to substance |
EXP |
SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of CPT1A protein]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PCK1 mRNA]; SIRT1 protein affects the reaction [Triiodothyronine results in increased expression of PDK4 mRNA] Triiodothyronine results in increased expression of SIRT1 mRNA SIRT1 protein affects the susceptibility to Triiodothyronine |
CTD |
PMID:23209300 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SLC10A2 mRNA |
CTD |
PMID:28299817 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
multiple interactions decreases expression |
ISO |
resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 mRNA]; resveratrol inhibits the reaction [Triiodothyronine results in decreased expression of SLC15A1 protein] Triiodothyronine results in decreased expression of SLC15A1 mRNA; Triiodothyronine results in decreased expression of SLC15A1 protein |
CTD |
PMID:26394120 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slc16a2 |
solute carrier family 16 member 2 |
multiple interactions increases uptake |
ISO |
bisphenol A inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; bosutinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Dasatinib inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Desipramine inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Genistein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Imatinib Mesylate inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Indocyanine Green inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Meclofenamic Acid inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Phloretin inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine]; Sulfobromophthalein inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine] |
CTD |
PMID:28119167 |
|
NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC16A3 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of SLC16A6 mRNA (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC16A6 mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr10:94,424,377...94,447,984
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC1A2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 3:89,005,129...89,126,498
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc25a25 |
solute carrier family 25 member 25 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SLC25A25 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 3:15,708,702...15,742,195
Ensembl chr 3:15,708,703...15,742,216
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC2A1 mRNA |
CTD |
PMID:15507505 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of SLC2A4 protein |
CTD |
PMID:27605626 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions |
EXP |
[Triiodothyronine co-treated with Fructose] results in increased expression of SLC2A5 mRNA |
CTD |
PMID:17485832 |
|
NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SLC38A2 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc43a2 |
solute carrier family 43 member 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC43A2 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:60,375,462...60,420,838
Ensembl chr10:60,376,559...60,418,244
|
|
G |
Slc51b |
solute carrier family 51 subunit beta |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of SLC51B mRNA (4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of SLC51B mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr 8:65,931,891...65,934,893
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Triiodothyronine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Sned1 |
sushi, nidogen and EGF-like domains 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SNED1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 9:93,774,087...93,834,003
Ensembl chr 9:93,774,119...93,830,694
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
ISO |
Triiodothyronine inhibits the reaction [Paraquat results in decreased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA] Triiodothyronine results in decreased expression of SOD1 mRNA |
CTD |
PMID:16738222 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Spen |
spen family transcriptional repressor |
increases expression |
ISO |
Triiodothyronine results in increased expression of SPEN mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 5:153,775,287...153,848,677
Ensembl chr 5:153,776,234...153,848,811
|
|
G |
Sptlc2 |
serine palmitoyltransferase, long chain base subunit 2 |
increases expression |
ISO |
Triiodothyronine results in increased expression of SPTLC2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 6:106,948,681...107,031,584
Ensembl chr 6:106,950,949...107,031,542
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO |
[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein] Triiodothyronine results in increased expression of SQSTM1 mRNA |
CTD |
PMID:24262987 PMID:30209975 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]] |
CTD |
PMID:22227104 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression decreases activity |
EXP ISO |
SIRT1 protein affects the reaction [Triiodothyronine results in decreased activity of SREBF1 protein]; SIRT1 protein affects the reaction [Triiodothyronine results in decreased expression of SREBF1 mRNA] [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA] |
CTD |
PMID:23209300 PMID:33476690 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srsf3 |
serine and arginine rich splicing factor 3 |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of SFRS3 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr20:7,091,928...7,101,860
Ensembl chr20:7,091,910...7,101,078
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA] |
CTD |
PMID:21726595 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stard8 |
StAR-related lipid transfer domain containing 8 |
increases expression |
ISO |
Triiodothyronine results in increased expression of STARD8 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr X:64,079,079...64,196,052
Ensembl chr X:64,124,574...64,196,052
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Triiodothyronine inhibits the reaction [FGF2 protein results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:16150908 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
increases expression |
ISO |
Triiodothyronine results in increased expression of STAT5A mRNA |
CTD |
PMID:25172293 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
increases expression |
EXP |
Triiodothyronine results in increased expression of STAT5B mRNA |
CTD |
PMID:15953391 |
|
NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
|
|
G |
Stk19 |
serine/threonine kinase 19 |
increases expression |
ISO |
Triiodothyronine results in increased expression of STK19 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr20:3,995,590...4,005,117
Ensembl chr20:3,995,587...4,005,116
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation multiple interactions affects sulfation |
ISO |
SULT1A1 protein results in increased sulfation of Triiodothyronine Triiodothyronine inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol] SULT1A1 gene polymorphism affects the sulfation of Triiodothyronine |
CTD |
PMID:11739018 PMID:15531517 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases expression |
EXP |
Triiodothyronine results in increased expression of SULT2A1 mRNA |
CTD |
PMID:15953391 |
|
NCBI chr 1:75,451,178...75,508,142
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Sult4a1 |
sulfotransferase family 4A, member 1 |
increases metabolic processing |
ISO |
SULT4A1 protein results in increased metabolism of Triiodothyronine |
CTD |
PMID:12039030 |
|
NCBI chr 7:115,216,066...115,240,156
Ensembl chr 7:115,216,066...115,240,085
|
|
G |
Taf5l |
TATA-box binding protein associated factor 5 like |
increases expression |
ISO |
Triiodothyronine results in increased expression of TAF5L mRNA |
CTD |
PMID:23397585 |
|
NCBI chr19:51,991,704...52,011,001
Ensembl chr19:51,991,708...52,011,295
|
|
G |
Tcim |
transcriptional and immune response regulator |
multiple interactions increases expression |
ISO |
SJ 000311413 inhibits the reaction [Triiodothyronine results in increased expression of TCIM mRNA] |
CTD |
PMID:21815645 |
|
NCBI chr16:67,595,762...67,597,055
Ensembl chr16:67,593,410...67,597,581
|
|
G |
Tex264 |
testis expressed 264 |
increases expression |
EXP |
Triiodothyronine results in increased expression of TEX264 mRNA |
CTD |
PMID:29357290 |
|
NCBI chr 8:107,295,806...107,322,858
Ensembl chr 8:107,295,806...107,323,232
|
|
G |
Tf |
transferrin |
multiple interactions |
ISO |
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; rosemarinic acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tfeb |
transcription factor EB |
increases expression |
ISO |
Triiodothyronine results in increased expression of TFEB mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP ISO |
Triiodothyronine inhibits the reaction [TGFB1 protein results in increased secretion of MMP2 protein]; Triiodothyronine promotes the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [rosemarinic acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:18031379 PMID:33476690 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgoln2 |
trans-golgi network protein 2 |
decreases expression increases expression |
ISO |
Triiodothyronine results in decreased expression of TGOLN2 mRNA Triiodothyronine results in increased expression of TGOLN2 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions affects binding increases expression increases activity decreases expression |
ISO EXP |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRA protein]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRA protein]; [THRA protein co-treated with Triiodothyronine] promotes the reaction [ANGPTL8 protein binds to PLIN3 protein]; [THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [THRA protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 protein; Ammonium Chloride inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; ANGPTL8 protein affects the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; bis(4-hydroxyphenyl)sulfone inhibits the reaction [Triiodothyronine binds to THRA protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRA protein]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRA protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRA protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased cleavage of CASP3 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CASP3 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of CYCS mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL1B mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of IL6 mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL1B protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of IL6 protein]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine binds to and results in increased activity of THRA protein; Triiodothyronine inhibits the reaction [THRA protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRA protein]; Triiodothyronine promotes the reaction [THRA protein binds to NCOA2 protein] 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine results in increased expression of THRA mRNA]; CSK protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine binds to THRA protein]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA]; Triiodothyronine inhibits the reaction [[NR4A1 co-treated with THRA] results in increased expression of STAR mRNA]; Triiodothyronine promotes the reaction [[NR4A1 co-treated with THRA] results in increased expression of HSD3B1 mRNA] [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRA mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRA mRNA; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRA protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine binds to THRA protein]; THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine binds to and results in increased activity of THRA protein Triiodothyronine results in decreased expression of THRA mRNA Triiodothyronine results in increased expression of THRA mRNA; Triiodothyronine results in increased expression of THRA protein |
CTD |
PMID:7684602 PMID:9664232 PMID:11806713 PMID:12109914 PMID:12414890 PMID:12588052 PMID:15680168 PMID:15708448 PMID:16021636 PMID:16023420 PMID:16738222 PMID:19672399 PMID:21396401 PMID:21726595 PMID:22015988 PMID:22086976 PMID:23112079 PMID:23402801 PMID:24076165 PMID:24262987 PMID:24819616 PMID:25646720 PMID:27993100 PMID:28167136 PMID:29146198 PMID:29688519 PMID:31566444 PMID:32223187 PMID:33049310 PMID:33095664 More...
|
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions decreases expression affects binding increases response to substance increases activity increases expression |
ISO EXP |
(4-(4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl)-3,5-dimethylphenoxy)acetic acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,2',4,4'-tetrabromodiphenyl ether analog affects the reaction [Triiodothyronine binds to THRB protein]; 2,2',4,4'-tetrabromodiphenyl ether metabolite inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,3,4,7,8-pentachlorodibenzofuran inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 2,4,6-tribromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-trichlorophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2,4,6-triiodophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; 4,4'-bisphenol F inhibits the reaction [Triiodothyronine binds to THRB protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Triiodothyronine binds to THRB protein]; 4-nonylphenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; 4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; 6-OH-BDE-47 inhibits the reaction [Triiodothyronine binds to THRB protein]; [THRB protein co-treated with Triiodothyronine] results in increased expression of ANGPTL8 mRNA; [Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; AG 1879 inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Amiodarone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bis(4-hydroxyphenyl)sulfone analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bis(4-hydroxyphenyl)sulfone analog inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bis(4-hydroxyphenyl)sulfone inhibits the reaction [Triiodothyronine binds to THRB protein]; bis(4-hydroxyphenyl)sulfone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; bisphenol A analog inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [[Triiodothyronine co-treated with NCOA1 protein] results in increased activity of THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; bisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; cyhalothrin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; daidzein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; deoxynivalenol inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein alternative form]; Genistein promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; ITGB3 inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; KB 130015 inhibits the reaction [Triiodothyronine binds to and results in increased activity of THRB protein]; methoxyacetic acid promotes the reaction [Triiodothyronine results in increased activity of THRB protein]; pentabromodiphenyl ether analog inhibits the reaction [Triiodothyronine binds to THRB protein]; pentabromophenol inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls metabolite inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]]]; SRC inhibits the reaction [bisphenol A inhibits the reaction [Triiodothyronine inhibits the reaction [NCOR2 protein binds to and results in decreased activity of THRB protein]]]; systhane inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; T-2 Toxin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrabromobisphenol A inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetrachlorodian analog inhibits the reaction [Triiodothyronine binds to THRB protein]; tetrachlorodian inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]]; tetraiodothyroacetic acid inhibits the reaction [Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]]; Thyroxine inhibits the reaction [Triiodothyronine binds to THRB protein]; Tretinoin inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; tribromodiphenyl ether 28 analog affects the reaction [Triiodothyronine binds to THRB protein]; Triclosan inhibits the reaction [Triiodothyronine binds to THRB protein]; Triiodothyronine binds to and results in increased activity of THRB protein; Triiodothyronine inhibits the reaction [NCOR1 protein binds to and results in decreased activity of THRB protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR1 protein]; Triiodothyronine inhibits the reaction [THRB protein binds to NCOR2 protein]; Triiodothyronine inhibits the reaction [THRB protein results in increased expression of SOD1 mRNA]; Triiodothyronine promotes the reaction [NCOA2 protein binds to THRB protein]; Triiodothyronine promotes the reaction [THRB protein binds to NCOA2 protein]; Zearalenone inhibits the reaction [Triiodothyronine results in increased activity of THRB protein] Triiodothyronine results in decreased expression of THRB mRNA THRB protein results in increased susceptibility to Triiodothyronine THRB protein promotes the reaction [Triiodothyronine results in decreased expression of CDKN1B protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of CCND1 protein]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of PCNA protein] Triiodothyronine results in increased expression of THRB mRNA; Triiodothyronine results in increased expression of THRB protein [bisphenol A co-treated with Estradiol co-treated with Triiodothyronine] results in increased expression of THRB mRNA; [bisphenol A co-treated with Triiodothyronine] results in increased expression of THRB mRNA; Butyric Acid inhibits the reaction [Triiodothyronine results in increased expression of THRB mRNA]; desethylamiodarone inhibits the reaction [Triiodothyronine binds to THRB protein]; Polybrominated Biphenyls inhibits the reaction [Triiodothyronine results in increased activity of THRB protein]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein promotes the reaction [Triiodothyronine results in increased expression of ATP2A2 mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB mRNA]; Triiodothyronine inhibits the reaction [Phenylephrine results in decreased expression of THRB protein] |
CTD |
PMID:2211641 PMID:8137729 PMID:11577024 PMID:11806713 PMID:12109914 PMID:12414890 PMID:12538616 PMID:12588052 PMID:15103026 PMID:15598685 PMID:15680168 PMID:15708448 PMID:16021636 PMID:16738222 PMID:18486176 PMID:18584933 PMID:18795168 PMID:19457453 PMID:19672399 PMID:20638743 PMID:20737425 PMID:21396401 PMID:22015988 PMID:22227104 PMID:23112079 PMID:23402801 PMID:24262987 PMID:25646720 PMID:27410513 PMID:27420076 PMID:27993100 PMID:28167136 PMID:28531659 PMID:28973306 PMID:29146198 PMID:29409039 PMID:29688519 PMID:29763311 PMID:31077750 PMID:31476497 PMID:31566444 PMID:33049310 PMID:33095664 More...
|
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Thrsp |
thyroid hormone responsive |
multiple interactions increases expression |
EXP ISO |
Triiodothyronine inhibits the reaction [Amiodarone results in increased expression of THRSP mRNA] Triiodothyronine results in increased expression of THRSP mRNA |
CTD |
PMID:2721112 PMID:10357836 PMID:15953391 PMID:28478156 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Tmem184b |
transmembrane protein 184B |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in increased expression of TMEM184B mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 7:110,925,092...110,967,975
Ensembl chr 7:110,925,092...110,967,943
|
|
G |
Tmem44 |
transmembrane protein 44 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TMEM44 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr11:70,181,120...70,216,958
Ensembl chr11:70,181,345...70,216,958
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF mRNA; [Triiodothyronine co-treated with Hexachlorocyclohexane] results in increased expression of TNF protein; Hexachlorocyclohexane inhibits the reaction [Triiodothyronine results in increased expression of TNF protein] THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]]; THRA protein affects the reaction [Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein]]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased expression of TNF mRNA]; Triiodothyronine inhibits the reaction [Silicon Dioxide results in increased secretion of TNF protein] |
CTD |
PMID:15019085 PMID:32223187 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TNFRSF9 protein] Triiodothyronine results in increased expression of TNFRSF9 mRNA; Triiodothyronine results in increased expression of TNFRSF9 protein |
CTD |
PMID:14761676 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of TOMM20 protein Chloroquine promotes the reaction [Triiodothyronine results in increased expression of TOMM20 protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
multiple interactions increases expression |
ISO |
4-OH-2',3,3',4',5'-pentachlorobiphenyl inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Polychlorinated Biphenyls inhibits the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 mRNA]; Tetrachlorodibenzodioxin promotes the reaction [Triiodothyronine results in increased expression of TRAF1 protein] Triiodothyronine results in increased expression of TRAF1 mRNA; Triiodothyronine results in increased expression of TRAF1 protein |
CTD |
PMID:14761676 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Trim46 |
tripartite motif-containing 46 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TRIM46 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:174,641,494...174,654,237
Ensembl chr 2:174,641,496...174,654,141
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
decreases expression multiple interactions increases secretion |
ISO EXP |
Triiodothyronine results in decreased expression of TSHB mRNA [Triiodothyronine co-treated with 2,2',4,4'-tetrabromodiphenyl ether] results in decreased expression of TSHB mRNA alternative form TSHB protein results in increased secretion of Triiodothyronine |
CTD |
PMID:7827627 PMID:9092800 PMID:11288978 PMID:27420076 PMID:28167136 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Ttbk1 |
tau tubulin kinase 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of TTBK1 mRNA |
CTD |
PMID:25172293 |
|
NCBI chr 9:14,493,166...14,538,372
Ensembl chr 9:14,493,389...14,535,774
|
|
G |
Ttn |
titin |
multiple interactions affects expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Triiodothyronine affects the expression of TTN mRNA]; AKT1 protein affects the reaction [Triiodothyronine affects the expression of TTN mRNA] |
CTD |
PMID:18096819 |
|
NCBI chr 3:61,652,432...61,924,912
Ensembl chr 3:61,652,439...61,924,741
|
|
G |
Ttr |
transthyretin |
affects binding |
ISO |
Triiodothyronine binds to TTR protein |
CTD |
PMID:20804816 PMID:21517007 |
|
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions increases expression |
ISO EXP |
(+)-JQ1 compound inhibits the reaction [[Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA]; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [Triiodothyronine co-treated with Rosiglitazone co-treated with INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of UCP1 mRNA [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] Triiodothyronine results in increased expression of UCP1 mRNA; Triiodothyronine results in increased expression of UCP1 protein [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [Triiodothyronine co-treated with Norepinephrine] results in increased expression of UCP1 mRNA; AVP protein inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; AVP protein inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]; Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA] |
CTD |
PMID:11742803 PMID:26972250 PMID:30209975 PMID:33091441 PMID:33476690 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
THRA protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; THRB protein alternative form affects the reaction [Triiodothyronine promotes the reaction [Thiazolidinediones results in increased expression of UCP2]]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased expression of UCP2 protein]; Triiodothyronine promotes the reaction [Bezafibrate results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [carboprostacyclin results in increased expression of UCP2 mRNA]; Triiodothyronine promotes the reaction [darglitazone results in increased expression of UCP2 mRNA] |
CTD |
PMID:12588052 PMID:25048947 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ugcg |
UDP-glucose ceramide glucosyltransferase |
increases activity |
EXP |
Triiodothyronine results in increased activity of UGCG protein |
CTD |
PMID:9101438 |
|
NCBI chr 5:74,032,978...74,065,701
Ensembl chr 5:74,032,978...74,065,393
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases expression multiple interactions |
EXP |
Triiodothyronine results in decreased expression of UGT1A1 mRNA Vitamin A inhibits the reaction [Triiodothyronine results in decreased expression of UGT1A1 mRNA] |
CTD |
PMID:11299074 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
increases expression multiple interactions |
EXP |
Triiodothyronine results in increased expression of UGT1A6 mRNA Vitamin A inhibits the reaction [Triiodothyronine results in increased expression of UGT1A6 mRNA] |
CTD |
PMID:11299074 |
|
NCBI chr 9:88,747,229...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Utp20 |
UTP20 small subunit processome component |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of UTP20 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr 7:23,134,630...23,215,639
Ensembl chr 7:23,134,637...23,215,632
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
increases expression multiple interactions |
ISO |
Triiodothyronine results in increased expression of VDAC1 protein Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA |
CTD |
PMID:33091441 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wls |
Wnt ligand secretion mediator |
increases expression |
ISO |
Triiodothyronine results in increased expression of WLS mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 2:248,931,885...249,047,248
Ensembl chr 2:248,931,903...249,048,298
|
|
G |
Zc3h7b |
zinc finger CCCH-type containing 7B |
decreases expression |
ISO |
Triiodothyronine results in decreased expression of ZC3H7B mRNA |
CTD |
PMID:23397585 |
|
NCBI chr 7:113,262,142...113,310,399
Ensembl chr 7:113,262,165...113,310,399
|
|
G |
Zfp113 |
zinc finger protein 3 |
multiple interactions |
ISO |
[Triiodothyronine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ZNF3 mRNA |
CTD |
PMID:14761676 |
|
NCBI chr12:17,022,104...17,033,776
Ensembl chr12:17,022,279...17,033,709
|
|
G |
Zfp664 |
zinc finger protein 664 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ZNF664 mRNA |
CTD |
PMID:23397585 |
|
|
|
G |
Zmiz1 |
zinc finger, MIZ-type containing 1 |
increases expression |
ISO |
Triiodothyronine results in increased expression of ZMIZ1 mRNA |
CTD |
PMID:23397585 |
|
NCBI chr16:1,027,083...1,232,616
Ensembl chr16:1,027,325...1,232,597
|
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
multiple interactions |
ISO |
[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine; Iodoacetates inhibits the reaction [[DIO1 protein results in increased metabolism of Triiodothyronine, Reverse] which results in increased abundance of 3,3'-diiodothyronine] |
CTD |
PMID:21565810 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO |
3,3'-diiodothyronine inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol] |
CTD |
PMID:15531517 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions |
EXP ISO |
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]]; 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein] [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Dizocilpine Maleate; [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Scopolamine; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein |
CTD |
PMID:12672554 PMID:15452191 PMID:19966059 |
|
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16116186 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression decreases response to substance |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of BIRC3 mRNA BIRC3 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine |
CTD |
PMID:16088125 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases response to substance |
ISO |
BIRC5 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine |
CTD |
PMID:16088125 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:16116186 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; Wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:16116186 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
decreases response to substance decreases expression |
ISO |
NAIP protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of NAIP mRNA |
CTD |
PMID:16088125 |
|
NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:15452191 PMID:19966059 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
EXP |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Slc9a1 |
solute carrier family 9 member A1 |
multiple interactions |
EXP |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein] |
CTD |
PMID:15452191 |
|
NCBI chr 5:145,576,341...145,629,630
Ensembl chr 5:145,576,334...145,629,624
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
3-iodo-2-propynylbutylcarbamate inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
3-iodo-2-propynylbutylcarbamate binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
3-iodo-2-propynylbutylcarbamate binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
3-iodo-2-propynylbutylcarbamate binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
3-iodo-2-propynylbutylcarbamate binds to and results in increased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
affects binding |
IDA |
4-DAMP methiodide inhibits response to acetylcholine in rat aortic rings |
RGD |
PMID:8075871 |
RGD:2303390 |
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
Clioquinol inhibits the reaction [[Copper co-treated with Cholesterol] results in increased activity of ACHE protein] |
CTD |
PMID:25856695 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
multiple interactions |
ISO |
[Clioquinol co-treated with zinc chloride] results in decreased expression of AGO2 mRNA; [Clioquinol co-treated with zinc chloride] results in decreased expression of AGO2 protein |
CTD |
PMID:22415087 |
|
NCBI chr 7:105,018,202...105,105,120
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Ak1 |
adenylate kinase 1 |
decreases expression |
ISO |
Clioquinol results in decreased expression of AK1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of AKT1 protein]; [Clioquinol co-treated with Copper] results in increased phosphorylation of AKT1 protein |
CTD |
PMID:16648635 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol binds to Copper] which results in increased degradation of APP protein modified form]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in decreased expression of APP protein alternative form]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Clioquinol binds to Copper] which results in increased degradation of APP protein modified form]; [Clioquinol binds to Copper] which results in increased degradation of APP protein modified form; [Clioquinol co-treated with Copper] results in decreased expression of APP protein alternative form; Clioquinol inhibits the reaction [Copper results in increased secretion of APP protein alternative form]; Clioquinol inhibits the reaction [Zinc results in increased secretion of APP protein alternative form]; pyrazolanthrone inhibits the reaction [[Clioquinol co-treated with Copper] results in decreased expression of APP protein alternative form] |
CTD |
PMID:16648635 PMID:18346929 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
[Clioquinol binds to Copper] which results in decreased expression of AR protein |
CTD |
PMID:17308104 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Clioquinol results in increased expression of ATF3 mRNA |
CTD |
PMID:32661532 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atm |
ATM serine/threonine kinase |
increases phosphorylation |
ISO |
Clioquinol results in increased phosphorylation of ATM protein |
CTD |
PMID:22627294 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
increases oxidation |
ISO |
Clioquinol results in increased oxidation of ATOX1 protein |
CTD |
PMID:33034664 |
|
NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression multiple interactions |
ISO |
Clioquinol results in decreased expression of ATP2A2 mRNA; Clioquinol results in decreased expression of ATP2A2 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Clioquinol results in decreased expression of ATP2A2 mRNA]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Clioquinol results in decreased expression of ATP2A2 protein]; Calcium promotes the reaction [Clioquinol results in decreased expression of ATP2A2 mRNA]; Calcium promotes the reaction [Clioquinol results in decreased expression of ATP2A2 protein] |
CTD |
PMID:33511738 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
decreases expression |
ISO |
Clioquinol results in decreased expression of BNIP3L mRNA |
CTD |
PMID:19502547 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Clioquinol inhibits the reaction [Isoflurane results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:17287498 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Clioquinol results in increased expression of CDKN1A mRNA |
CTD |
PMID:22627294 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
affects response to substance |
ISO |
COMMD1 gene SNP affects the susceptibility to Clioquinol |
CTD |
PMID:25622337 |
|
NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501
|
|
G |
Dbh |
dopamine beta-hydroxylase |
increases expression decreases secretion |
ISO |
Clioquinol results in increased expression of DBH mRNA Clioquinol results in decreased secretion of DBH protein |
CTD |
PMID:33034664 |
|
NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Dicer1 |
dicer 1 ribonuclease III |
multiple interactions |
ISO |
[Clioquinol co-treated with zinc chloride] results in decreased expression of DICER1 protein |
CTD |
PMID:22415087 |
|
NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965
|
|
G |
Drosha |
drosha ribonuclease III |
multiple interactions |
ISO |
[Clioquinol co-treated with zinc chloride] affects the expression of DROSHA protein |
CTD |
PMID:22415087 |
|
NCBI chr 2:61,864,886...61,976,688
Ensembl chr 2:61,864,970...61,976,688
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of EGFR protein]; [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK1 protein]; [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK3 protein]; [[Clioquinol binds to Copper] which results in increased activity of SRC protein] which results in increased phosphorylation of and results in increased activity of EGFR protein; [Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein; [FN1 protein co-treated with [Clioquinol binds to Copper]] results in increased expression of EGFR protein; AG 1879 inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of EGFR protein]; FN1 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein]; ITGA2 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein]; ITGA5 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] |
CTD |
PMID:18346929 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
decreases expression |
ISO |
Clioquinol results in decreased expression of EGLN1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr19:52,867,914...52,907,169
Ensembl chr19:52,869,486...52,907,777
|
|
G |
Egln2 |
egl-9 family hypoxia-inducible factor 2 |
decreases expression |
ISO |
Clioquinol results in decreased expression of EGLN2 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 1:82,451,554...82,459,809
Ensembl chr 1:82,451,555...82,459,751
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Clioquinol results in increased expression of EGR1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
[Clioquinol co-treated with zinc chloride] results in increased expression of EIF4E mRNA; [Clioquinol co-treated with zinc chloride] results in increased expression of EIF4E protein |
CTD |
PMID:22415087 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Epo |
erythropoietin |
increases expression decreases expression |
ISO |
Clioquinol results in increased expression of EPO mRNA Clioquinol results in decreased expression of EPO mRNA |
CTD |
PMID:16973622 PMID:19502547 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[FN1 protein co-treated with [Clioquinol binds to Copper]] results in increased expression of EGFR protein; FN1 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] |
CTD |
PMID:18346929 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Clioquinol promotes the reaction [FOS protein binds to CXCL8 promoter] |
CTD |
PMID:29966605 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
Clioquinol results in increased expression of GADD45A mRNA |
CTD |
PMID:22627294 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gata2 |
GATA binding protein 2 |
decreases expression multiple interactions |
ISO |
Clioquinol results in decreased expression of GATA2 protein GATA2 protein inhibits the reaction [Clioquinol results in increased expression of CXCL8 mRNA]; GATA2 protein inhibits the reaction [Clioquinol results in increased secretion of CXCL8 protein] |
CTD |
PMID:29966605 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gata3 |
GATA binding protein 3 |
decreases expression multiple interactions |
ISO |
Clioquinol results in decreased expression of GATA3 protein Clioquinol inhibits the reaction [GATA3 protein binds to CXCL8 promoter]; GATA3 protein inhibits the reaction [Clioquinol results in increased expression of CXCL8 mRNA]; GATA3 protein inhibits the reaction [Clioquinol results in increased secretion of CXCL8 protein] |
CTD |
PMID:29966605 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Clioquinol results in increased phosphorylation of H2AX protein |
CTD |
PMID:22627294 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression decreases hydroxylation decreases ubiquitination increases activity |
ISO |
[Zinc co-treated with Copper] inhibits the reaction [Clioquinol results in increased expression of HIF1A protein]; Clioquinol inhibits the reaction [HIF1AN protein results in increased hydroxylation of HIF1A protein] [Clioquinol co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HIF1A protein; HIF1A protein promotes the reaction [Clioquinol results in increased expression of VEGFA protein] Clioquinol results in decreased hydroxylation of HIF1A protein Clioquinol results in decreased ubiquitination of HIF1A protein Clioquinol results in increased activity of HIF1A protein |
CTD |
PMID:16973622 PMID:19502547 PMID:19679656 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hif1an |
hypoxia inducible factor 1 subunit alpha inhibitor |
multiple interactions decreases activity |
ISO |
Clioquinol inhibits the reaction [HIF1AN protein results in increased hydroxylation of HIF1A protein] Clioquinol results in decreased activity of HIF1AN protein |
CTD |
PMID:16973622 |
|
NCBI chr 1:243,419,175...243,440,464
Ensembl chr 1:243,419,194...243,434,327
|
|
G |
Hif3a |
hypoxia inducible factor 3 subunit alpha |
decreases expression |
ISO |
Clioquinol results in decreased expression of HIF3A mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 1:77,718,110...77,750,448
Ensembl chr 1:77,722,471...77,749,758
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Clioquinol results in increased expression of HMOX1 mRNA |
CTD |
PMID:32661532 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO |
ITGA2 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] |
CTD |
PMID:18346929 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itga5 |
integrin subunit alpha 5 |
multiple interactions |
ISO |
ITGA5 protein promotes the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of EGFR protein] |
CTD |
PMID:18346929 |
|
NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Clioquinol promotes the reaction [JUN protein binds to CXCL8 promoter] |
CTD |
PMID:29966605 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lox |
lysyl oxidase |
increases expression decreases secretion |
ISO |
Clioquinol results in increased expression of LOX mRNA Clioquinol results in decreased secretion of LOX protein |
CTD |
PMID:33034664 |
|
NCBI chr18:45,964,311...46,041,477
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of MAPK1 protein]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of MAPK1 protein]; [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK1 protein]; [Clioquinol binds to Copper] which results in increased phosphorylation of MAPK1 protein; [Clioquinol co-treated with Copper] results in increased phosphorylation of MAPK1 protein; [Clioquinol co-treated with Zinc] results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:16648635 PMID:18346929 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of MAPK3 protein]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of MAPK3 protein]; [4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline results in decreased phosphorylation of and results in decreased activity of EGFR protein] inhibits the reaction [[Copper binds to Clioquinol] which results in increased phosphorylation of MAPK3 protein]; [Clioquinol binds to Copper] which results in increased phosphorylation of MAPK3 protein; [Clioquinol co-treated with Copper] results in increased phosphorylation of MAPK3 protein; [Clioquinol co-treated with Zinc] results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [[Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:16648635 PMID:18346929 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Clioquinol co-treated with Copper] results in increased phosphorylation of MAPK8 protein; [Clioquinol co-treated with Zinc] results in increased phosphorylation of MAPK8 protein; pyrazolanthrone inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:16648635 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases expression |
ISO |
Clioquinol results in increased expression of MIF mRNA |
CTD |
PMID:19502547 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mir130a |
microRNA 130a |
multiple interactions |
ISO |
[Clioquinol co-treated with zinc chloride] results in decreased expression of MIR130A mRNA |
CTD |
PMID:22415087 |
|
NCBI chr 3:69,822,542...69,822,629
Ensembl chr 3:69,822,542...69,822,629
|
|
G |
Mir223 |
microRNA 223 |
multiple interactions |
ISO |
[Clioquinol co-treated with zinc chloride] results in decreased expression of MIR223 mRNA |
CTD |
PMID:22415087 |
|
NCBI chr X:61,141,887...61,141,996
Ensembl chr X:61,141,887...61,141,996
|
|
G |
Mir29a |
microRNA 29a |
multiple interactions |
ISO |
[Clioquinol co-treated with zinc chloride] results in decreased expression of MIR29A mRNA |
CTD |
PMID:22415087 |
|
NCBI chr 4:59,650,608...59,650,695
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Clioquinol co-treated with Copper] results in increased expression of and results in increased activity of MMP2 protein |
CTD |
PMID:16648635 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
[Clioquinol co-treated with Copper] results in increased expression of and results in increased activity of MMP3 protein |
CTD |
PMID:16648635 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Clioquinol inhibits the reaction [MOG protein results in increased activity of MMP9 protein] |
CTD |
PMID:23360710 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mog |
myelin oligodendrocyte glycoprotein |
multiple interactions |
ISO |
Clioquinol inhibits the reaction [MOG protein results in increased activity of MMP9 protein] |
CTD |
PMID:23360710 |
|
NCBI chr20:1,513,137...1,523,473
Ensembl chr20:1,513,239...1,523,474
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Clioquinol inhibits the reaction [NGF protein results in increased phosphorylation of NTRK1 protein]; trichostatin A inhibits the reaction [Clioquinol inhibits the reaction [NGF protein results in increased phosphorylation of NTRK1 protein]] |
CTD |
PMID:25758465 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
multiple interactions |
ISO |
Clioquinol inhibits the reaction [NGF protein results in increased phosphorylation of NTRK1 protein]; trichostatin A inhibits the reaction [Clioquinol inhibits the reaction [NGF protein results in increased phosphorylation of NTRK1 protein]] |
CTD |
PMID:25758465 |
|
NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
|
|
G |
P4ha2 |
prolyl 4-hydroxylase subunit alpha 2 |
decreases expression |
ISO |
Clioquinol results in decreased expression of P4HA2 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr10:38,243,047...38,271,989
Ensembl chr10:38,243,139...38,287,314
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression |
ISO |
Clioquinol results in increased expression of PGK1 mRNA |
CTD |
PMID:19502547 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[[Clioquinol binds to Copper] which results in increased activity of SRC protein] which results in increased phosphorylation of and results in increased activity of EGFR protein; [Clioquinol binds to Copper] which results in increased phosphorylation of and results in increased activity of SRC protein |
CTD |
PMID:18346929 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases phosphorylation |
ISO |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Clioquinol results in increased phosphorylation of TP53 protein] |
CTD |
PMID:22627294 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression decreases expression multiple interactions |
ISO |
Clioquinol results in increased expression of VEGFA mRNA; Clioquinol results in increased expression of VEGFA protein Clioquinol results in decreased expression of VEGFA mRNA HIF1A protein promotes the reaction [Clioquinol results in increased expression of VEGFA protein] |
CTD |
PMID:16973622 PMID:19502547 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vopp1 |
VOPP1 WW domain binding protein |
decreases expression |
ISO |
Clioquinol results in decreased expression of ECOP mRNA |
CTD |
PMID:19502547 |
|
NCBI chr 4:87,363,678...87,432,747
Ensembl chr 4:87,363,477...87,450,375
|
|
|
G |
Mbd4 |
methyl-CpG binding domain 4 DNA glycosylase |
affects response to substance |
ISO |
MBD4 protein affects the susceptibility to Idoxuridine |
CTD |
PMID:16885370 |
|
NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
Idoxuridine results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
multiple interactions |
EXP |
Idoxuridine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] |
CTD |
PMID:8713072 |
|
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
|
|
G |
Tyms |
thymidylate synthetase |
affects uptake |
ISO |
TYMS protein affects the uptake of Idoxuridine |
CTD |
PMID:15001691 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases phosphorylation |
EXP |
5-iodotubercidin results in decreased phosphorylation of CDKN1B protein |
CTD |
PMID:26953159 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Clk1 |
CDC-like kinase 1 |
decreases activity |
ISO |
5-iodotubercidin results in decreased activity of CLK1 protein |
CTD |
PMID:26953159 |
|
NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000
|
|
G |
Clk3 |
CDC-like kinase 3 |
decreases activity |
ISO |
5-iodotubercidin results in decreased activity of CLK3 protein |
CTD |
PMID:26953159 |
|
NCBI chr 8:58,152,155...58,167,196
Ensembl chr 8:58,152,155...58,168,181
|
|
G |
Clk4 |
CDC-like kinase 4 |
decreases activity |
ISO |
5-iodotubercidin results in decreased activity of CLK4 protein |
CTD |
PMID:26953159 |
|
NCBI chr10:35,523,382...35,541,387
Ensembl chr10:35,524,755...35,541,352
|
|
G |
Dyrk1a |
dual specificity tyrosine phosphorylation regulated kinase 1A |
decreases activity |
ISO |
5-iodotubercidin results in decreased activity of DYRK1A protein |
CTD |
PMID:26953159 |
|
NCBI chr11:33,890,706...34,009,420
Ensembl chr11:33,890,490...34,009,420
|
|
G |
Dyrk1b |
dual specificity tyrosine phosphorylation regulated kinase 1B |
decreases activity |
ISO |
5-iodotubercidin results in decreased activity of DYRK1B protein |
CTD |
PMID:26953159 |
|
NCBI chr 1:83,479,139...83,497,011
Ensembl chr 1:83,479,147...83,487,169
|
|
G |
Dyrk2 |
dual specificity tyrosine phosphorylation regulated kinase 2 |
decreases activity |
ISO |
5-iodotubercidin results in decreased activity of DYRK2 protein |
CTD |
PMID:26953159 |
|
NCBI chr 7:54,348,724...54,381,363
Ensembl chr 7:54,349,610...54,380,106
|
|
G |
Dyrk3 |
dual specificity tyrosine phosphorylation regulated kinase 3 |
decreases activity |
ISO |
5-iodotubercidin results in decreased activity of DYRK3 protein |
CTD |
PMID:26953159 |
|
NCBI chr13:42,594,120...42,604,898
Ensembl chr13:42,594,121...42,604,778
|
|
G |
Dyrk4 |
dual specificity tyrosine phosphorylation regulated kinase 4 |
decreases activity |
ISO |
5-iodotubercidin results in decreased activity of DYRK4 protein |
CTD |
PMID:26953159 |
|
NCBI chr 4:159,715,658...159,757,660
Ensembl chr 4:159,715,417...159,757,627
|
|
G |
Ins2 |
insulin 2 |
increases secretion affects secretion |
ISO |
5-iodotubercidin results in increased secretion of INS protein 5-iodotubercidin affects the secretion of INS protein |
CTD |
PMID:26953159 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
5-iodotubercidin results in increased expression of MMP3 mRNA |
CTD |
PMID:26953159 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Nefm |
neurofilament medium chain |
increases expression |
ISO |
5-iodotubercidin results in increased expression of NEFM mRNA |
CTD |
PMID:26953159 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Olfm4 |
olfactomedin 4 |
decreases expression |
ISO |
5-iodotubercidin results in decreased expression of OLFM4 mRNA |
CTD |
PMID:26953159 |
|
NCBI chr15:55,385,100...55,429,687
Ensembl chr15:55,407,148...55,429,681
|
|
G |
Reg3b |
regenerating family member 3 beta |
decreases expression |
ISO |
5-iodotubercidin results in decreased expression of REG3A mRNA |
CTD |
PMID:26953159 |
|
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
increases expression |
ISO |
5-iodotubercidin results in increased expression of SLC2A2 mRNA |
CTD |
PMID:26953159 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases expression |
ISO |
4'-methoxy-1-naphthylfenoterol inhibits the reaction [AM 251 results in increased expression of ABCG2 protein]; 4-(4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1H,4H,5H,6H-pyrrolo(3,4-c)pyrazol-5-yl)benzoic acid inhibits the reaction [AM 251 results in increased expression of ABCG2 protein] |
CTD |
PMID:27423937 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
AM 251 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agrp |
agouti related neuropeptide |
multiple interactions increases expression |
EXP |
AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA] AM 251 results in increased expression of AGRP mRNA |
CTD |
PMID:26468265 |
|
NCBI chr19:33,447,992...33,523,068
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
AM 251 inhibits the reaction [Cannabidiol results in increased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [Dronabinol results in decreased phosphorylation of and results in decreased activity of AKT1 protein] AM 251 inhibits the reaction [[3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide co-treated with Glutamic Acid] results in increased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [[cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester co-treated with Glutamic Acid] results in increased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [[JZL 184 co-treated with Glutamic Acid] results in increased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [Dietary Fats results in decreased expression of AKT1 protein] |
CTD |
PMID:17583570 PMID:26847930 PMID:27543109 PMID:33817834 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Arpc4 |
actin related protein 2/3 complex, subunit 4 |
decreases expression |
ISO |
AM 251 results in decreased expression of ARPC4 mRNA |
CTD |
PMID:16500647 |
|
NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:146,522,176...146,532,785
|
|
G |
Arpp21 |
cAMP regulated phosphoprotein 21 |
increases expression |
ISO |
AM 251 results in increased expression of ARPP21 mRNA |
CTD |
PMID:16500647 |
|
NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression |
ISO |
AM 251 results in increased expression of ASS1 mRNA |
CTD |
PMID:16500647 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
AM 251 results in increased expression of ATF5 mRNA |
CTD |
PMID:16500647 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Avp |
arginine vasopressin |
multiple interactions increases expression |
EXP |
AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA] AM 251 results in increased expression of AVP mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
AM 251 results in increased expression of BCL2 protein AM 251 inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein] |
CTD |
PMID:26967640 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions |
ISO |
AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] |
CTD |
PMID:19022239 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
AM 251 inhibits the reaction [Morphine results in increased expression of BDNF protein] |
CTD |
PMID:27461790 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
multiple interactions |
ISO |
AM 251 inhibits the reaction [Ethanol results in increased expression of BTG2 mRNA] |
CTD |
PMID:28095641 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Cap2 |
cyclase associated actin cytoskeleton regulatory protein 2 |
decreases expression |
ISO |
AM 251 results in decreased expression of CAP2 mRNA |
CTD |
PMID:16500647 |
|
NCBI chr17:18,054,234...18,203,453
Ensembl chr17:18,054,431...18,203,373
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
increases expression |
ISO |
AM 251 results in increased expression of CARS1 mRNA |
CTD |
PMID:16500647 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Cartpt |
CART prepropeptide |
increases expression multiple interactions |
EXP |
AM 251 results in increased expression of CARTPT mRNA [AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
AM 251 inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]] |
CTD |
PMID:34269108 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Cavin2 |
caveolae associated protein 2 |
decreases expression |
ISO |
AM 251 results in decreased expression of CAVIN2 mRNA |
CTD |
PMID:16500647 |
|
NCBI chr 9:50,302,079...50,314,096
Ensembl chr 9:50,301,206...50,314,147
|
|
G |
Ccdc86 |
coiled-coil domain containing 86 |
decreases expression |
ISO |
AM 251 results in decreased expression of CCDC86 mRNA |
CTD |
PMID:16500647 |
|
NCBI chr 1:207,590,946...207,596,527
Ensembl chr 1:207,590,168...207,596,544
|
 |